Overview

A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding

Status:
Unknown status

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to demonstrate that a regimen using highly active antiretroviral therapy (HAART) to maximally suppress maternal viral load in the late antenatal period and during the first six months of lactation is safe, effective and can be implemented in resource poor settings in order to reduce the risk of HIV transmission to the infant.

Phase:

Phase 2

Details

Lead Sponsor:

Centers for Disease Control and Prevention

Treatments:

Lamivudine
Nelfinavir
Nevirapine
Zidovudine